INMED PHARMACEUTICALS INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures
INMED PHARMACEUTICALS INC. (INM) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures of 61.72 thousand shares for the 9-month period ending 2023-03-31, per its 10-Q filed 2023-05-15.
Discontinued › Shareholders' Equity › Shares Granted or Issued, Share-Based Payment Arrangement
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod · last filed 2023-05-15
- INMED PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2023-03-31 was 0.00 shares.
- INMED PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2022-12-31 was 61.16K shares.
- INMED PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2022-09-30 was 560.00 shares.
- INMED PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2022 was 31.16K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 12 month |
|---|---|---|---|---|
| 2023-03-31 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-15 | 61.16K shares derived: sum of 2 quarters · filed 2023-05-15 | 61.72K shares 10-Q · filed 2023-05-15 | |
| 2022-12-31 | 61.16K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-02-17 | 61.72K shares 10-Q · filed 2023-02-17 | ||
| 2022-09-30 | 560.00 shares 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | 31.16K shares 10-K · filed 2022-09-23 | |||
| 2021-12-31 | 716.00K shares 10-Q · filed 2022-02-14 | |||
| 2021-06-30 | 765.00K shares 10-Q · filed 2022-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |